Objectives: To assess the awareness, among dental practi tioners, of the use of bisphosphonates (BP) and its compli cations related to dental extractions as well as to outline protocol for its prevention and management.
INTRODUCTION
Bisphosphonates (BP) are primarily used in the treatment and management of cancer-related conditions, including hypercalcemia of malignancy, skeletal-related events associated with bone metastases in the context of solid tumors, such as breast cancer, prostate cancer and lung cancer, and management of lytic lesions in the setting of multiple myeloma. Also, used in prevention and treatment of bone fragility diseases, like the osteitis deformans ('Paget's disease of bone'), primary hyperparathyroidism, osteogenesis imperfecta, fibrous dysplasia, and other conditions that feature bone fragility, such as osteop orosis, osteopenia, etc. 1 Bisphosphonates do not improve cancer-specific survival, but it has a significant positive effect on the quality of life for patients with advanced cancer involving the skeleton. Bisphosphonate-related osteoradionecrosis of jaws (BRONJ) is one of the major complications of BS therapy. In 2003, Marx reported BRONJ or bisphosphonateinduced osteonecrosis of the jaw (BIONJ), as a side-effect of BP treatment.
2 BRONJ lesions are defined as exposed necrotic bone without evidence of healing for at least 8 weeks in the maxillofacial area in patients with a history of BP use without a history of head and neck irradiation. 3 An incidence of 1 in 140,000 person life years of exposure associated with the orally administered drugs was originally based on BRONJ cases reported to pharmaceutical companies. The risk of developing BON increased more than four-fold when individuals underwent a dental extraction. It is necessary to create the awareness among dental practitioners and budding dentists regarding the BRONJ, its prevention and treatment protocol. Purpose of this study is to assess the awareness of dentists regarding BP and its dental-related complications and to outline the prevention and treatment protocol. This study was carried out in MGM Dental College and Hospital, Kamothe, Navi Mumbai, in December 2013. 
MATERIALS AND METHODS

Interns
DISCUSSION
Bisphosphonates are said to inhibit osteoclastic bone resorption and bone remodeling by inhibiting osteoclast differentiation and function and promoting apoptosis. [4] [5] [6] [7] [8] [9] Since the bone turnover rate is highest in maxilla and mandible, these are the most vulnerable sites for its occurrence. 10, 11 Other factor in pathophysiology is inhibition of angiogenesis. Osteonecrosis itself is a form of avascular necrosis, so inbibition of angiogenesis is thought to be responsible for occurrence of osteone c rosis.
Infection and inflammation is also thought to be a cause. In the biopsy specimen, actinomyces species was found. 12 In this study, 33 out of 39 (84.61%), 20 out of 25 (68.96%) and 81 out of 95 (85.26%) were aware of clinical use of BP. Patients with metastatic disorders and hypercalcemia are treated with IV BP.
2 Postmenopausal women presenting osteoporosis or osteopetrosis are prescribed with oral BP. It becomes important to take necessary precautions in these patients before undergoing any major or minor oral surgical procedure. Pamidronate, zoledronic acid are injectable BP and alendronate and risidronate are oral formulations. 2 The typical presentation of disease is of nonhealing extraction socket or exposed jawbone with progression to sequestrum formation associated with localized swelling and purulent discharge. 4 Diagnostic criterion is according to AAOMS definition, clinical and radiological findings, also biopsy, can be taken to rule out malignancy. 2 It is important to understand that patients at risk of, or with established, BRONJ can also present with other common clinical conditions not to be confused with BRONJ. In this study, eight staff out of 39, six postgraduate students of 25 and 23 interns of 95 were unaware of term BRONJ and its presentation. Commonly misdiagnosed conditions can include, but are not limited to, alveolar osteitis, sinusitis, gingivitis/periodontitis, caries, periapical pathologic findings, and temporomandibular joint disorders.
CLINICAL PRESENTATION
The site of involvement may be an area of prior trauma, such as an extraction or irritation from a dental prosthesis, although spontaneous osteonecrosis also can occur. The extent of symptoms and clinical disease shows varied presentation despite of similar disease processes, Graph 6: Did you in the past ever ask your patients for history of bisphosphonates before dental extractions
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Can you prevent BRONJ in dental patients undergoing extractions bisphosphonate dose and treatment duration. A staging system was based on these observations, developed that facilitates the clinical stratification of this disease process and guides treatment strategies.
• Stage 0: Signs and symptoms short of exposed necrotic bone that might indicate a histologic necrosis or a pre necrotic state.
• Stage 1: Exposed necrotic bone that is asymptomatic.
• Stage 2: Exposed, necrotic bone associated with pain and adjacent or regional soft-tissue involvement.
• Stage 3: Necrotic bone with associated pain and adjacent or regional soft-tissue infection and a pathologic fracture, extraoral fistula or osteolysis extending to the inferior border.
MANAGEMENT PROTOCOL
• For prevention of BRONJ: Every patient who is going to start on BP therapy should be scanned for dental foci of infection and the focus if present should be attended and solved before the therapy starts, this will prevent the occurrence of BRONJ. 37 Out of 39 staff (94.86%), four out of 25 (16%) postgraduate students and 21 out of 95 (22.10%) interns have asked patients about history of BP use. Patients should be looked for caries, periodontal disease; any minor oral surgical treatment should be performed well before the BP therapy initiation. Nonrestorable teeth and teeth with poor prognosis should be extracted before hand patients with complete or partial dentures should be looked for areas of irritation over mucosa and mainly in lingual flange region. Early dental screening and initiation of appropriate treatment has found to reduce the incidence BRONJ. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] It is important to find out potential sites of infection along with the focus of acute infection in order to prevent further sequel which could get exacerbated when therapy is initiated. It is important to educate the patients regarding oral hygiene and regular dental checkup. Patients are asked to report immediately if any pain, swelling or exposed bone. Dimopoulos found a statistically significant, almost threefold reduction in the incidence of osteonecrosis in patients when preventive measures were applied. 30 Drug holiday is another concept to prevent the risk of BRONJ. It involves temporary cessation of therapy before the invasive dental procedure, if systemic condition permits. American Association of Oral and Maxillofacial Surgeons (AAOMS) (2009) recommends discontinuing of BP therapy 3 months prior and 3 months after the invasive dental procedure. 31 Patients having BP exposure for more than 4 years are at higher-risk for BRONJ, therefore, drug holiday is beneficial in such cases. It is advised to continue BP therapy in patients with BP exposure of less than 2 years. 23 They note that since 50% of serum BP undergoes renal excretion the major reservoir of BP is the osteoclast whose life span is 2 weeks. Thus, the majority of free BP within the serum would be extremely low 2 months following the last dose of an oral BP and a 2-month drug-free period should be adequate prior to an invasive dental procedure. Patients physician should be contacted prior to any dental procedure with regards to discontinuation of BP drugs.
TREATMENT OF BRONJ
Patients with BRONJ
The treatment objectives for patients with an established diagnosis of BRONJ are to eliminate pain, control infection of the soft and hard tissue, and minimize the progression or occurrence of bone necrosis. [32] [33] [34] [35] [36] [37] • Regardless of the disease stage, mobile segments of bony sequestrum should be removed without exposing uninvolved bone. The extraction of symptomatic teeth within exposed, necrotic bone should be considered, since it is unlikely that the extraction will exacerbate the established necrotic process. General dental practitioners should seek the opinion and advice of the oncologist managing the patient with regards to discontinuation of intravenous BP therapy. Oral and maxillofacial surgeon should be involved with regards to management of BP-related osteoradionecrosis of the jaws.
CONCLUSION
There is lack of complete awareness regarding the side effects and guidelines for management of BP-related osteoradionecrosis of the jaws. It is a very important to find out patients who are at risk of BRONJ or who have developed the same. Meticulous examination and treatment is the need. So, it is very important to develop awareness regarding BP use and its complications among the dental professionals.
